SCHEDULE 13G/A: OrbiMed Affiliates Amend SEC Filing, Disclosing Combined 9.7% Stake in C4 Therapeutics

OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, detailing their beneficial ownership of 9.7% of C4 Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital LLC filed Amendment No. 1 to their Schedule 13G regarding C4 Therapeutics, Inc. common stock.
• As of March 31, 2025, OrbiMed Advisors LLC beneficially owns 2,174,700 shares, representing 3.1% of the class.
• OrbiMed Capital LLC beneficially owns 4,655,600 shares, representing 6.6% of the class.
• Collectively, the Reporting Persons hold an aggregate of 9.7% of C4 Therapeutics' common stock.
• OrbiMed Advisors LLC has shared voting and dispositive power over its shares, while OrbiMed Capital LLC has sole voting and dispositive power over its shares.
• The shares are held on behalf of other persons who have the right to receive dividends or proceeds from sale.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership. It contains no explicit positive or negative operational news, hence a neutral score.

Positives

• Significant institutional investment by OrbiMed, a specialized healthcare investment firm, which could be seen as a vote of confidence in C4 Therapeutics.

Future Outlook

This Schedule 13G/A filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding C4 Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• "The undersigned hereby agree that this Amendment No. 1 to the Statement on Schedule 13G... is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Joint Filing Agreement shall be included as an Exhibit to this Schedule 13G."
• "Each of the undersigned agrees to be responsible for the timely filing of this Schedule 13G and for the completeness and accuracy of the information concerning itself contained therein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing reflects a significant institutional investment by OrbiMed, a prominent healthcare-focused investment firm, in C4 Therapeutics, a biotechnology company. Such disclosures are common for large institutional investors holding over 5% of a company's stock, indicating their position in the market and their investment strategy within the biotechnology sector.

Comparison to Industry Standards

• As a standard Schedule 13G/A filing, this document primarily serves as a regulatory disclosure of beneficial ownership by institutional investors.
• It does not provide comparative financial or operational data for C4 Therapeutics against industry benchmarks or competitors.
• The filing confirms OrbiMed's substantial stake, which is typical for large investment funds specializing in specific sectors like biotechnology, but offers no direct comparison to other companies' investment profiles or performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Management: Awareness of a large institutional holder like OrbiMed may influence strategic decisions, though the filing states the stake is not for control purposes.

Key Dates

Keywords

C4 Therapeutics, OrbiMed Advisors, OrbiMed Capital, Schedule 13G/A, beneficial ownership, common stock, SEC filing, investment advisor, biotechnology investment